CEFIM-3 Suspension

Patients with known hypersensitivity to Cephalosporin group of drugs.

The majority of adverse reactions observed in clinical trials were mild and self-limiting in nature. Among them diarrhea, changes in the color of stool, nausea, abdominal pain, dyspepsia, headache, dizziness, elevation of serum amylase may occur.

In common with other Cephalosporins, increases in prothrombin times have been noted in a few patients. Care should therefore be taken in patients receiving anticoagulant therapy. A false positive

Pregnancy category B. Reproduction studies was performed in mice and rats at doses up to 400 times the human dose and revealed no evidence of impaired fertility or farm to the fetus due to Cefixime.

There are no adequate and well controlled studies in pregnant women. Therefore, Cefixime should not be used in pregnancy or in nursing mothers unless considered essential by the physicians reaction for glucose in the urine may occur with Benedict’s or Fehling’s solutions or with copper sulphate test tablets, but not with test based on enzymatic glucose oxidase reactions.

Cefixime should be prescribed with caution in individuals with a history of gastrointestinal diseases, particularly colitis. Dosage adjustment is only necessary in severe renal failure.

Cefixime is a broad spectrum Cephalosporin antibiotic of third generation for oral administration. It is a bactericidal antibiotic and is stable to hydrolysis by many beta-lactamases. Cefixime kills bacteria by interfering in the synthesis of the bacterial cell wall. 40-50% of an oral dose is absorbed from gastrointestinal tract, whether taken with meals or not. The plasma half-life is usually about 3-4 hours and may be prolonged when there is renal impairment. Cefim-3 is mainly excreted unchanged in bile and urine.